Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Predictive value of cobalt chloride solution for hypohidrosis with topiramate

약물 유발 소한증에서 cobalt chloride solution의 임상적 유용성

  • Lee, Hyuk (Department of Pediatrics, College of Medicine Chonbuk National University) ;
  • Lee, Seung Hyun (Department of Pediatrics, College of Medicine Chonbuk National University) ;
  • Kim, Sun Jun (Department of Pediatrics, College of Medicine Chonbuk National University)
  • 이혁 (전북대학교 의과대학 소아과학교실) ;
  • 이승현 (전북대학교 의과대학 소아과학교실) ;
  • 김선준 (전북대학교 의과대학 소아과학교실)
  • Received : 2006.07.10
  • Accepted : 2006.09.13
  • Published : 2006.11.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The aims of this study were to verify the incidence of hypohidrosis and to determine the predictive value of noninvasive indicator test ($Neurocheck^{TM}$) for sweating after administration of topiramate in newly diagnosed pediatric epileptic patients. Methods : A total of 46 epileptic patients (22 boys; 24 girls) on topiramate treatment were evaluated in this study at the Department of Pediatrics, Chonbuk National University Hospital, from October 2004 to July 2005. We measured sweating functions using a noninvasive sweating test ($Neurocheck^{TM}$) before topiramate medication, and after 3 months when topiramate reached its target dosage. We performed a direct questionnaire survey for the hypohidrosis related symptoms during topiramate treatment. Results : The mean age was $7.8{\pm}3.2year$. The mean dosage of topiramate was $4.5{\pm}0.8mg/kg/day$. Among the patients, there were 40 complex partial seizures, one simple partial seizure, two partial seizures with secondarily generalization, two generalized seizures, and one Lennox-Gastaut syndrome case. Of the 46 epileptic patients, 17 patients (37.0 percent) experienced hypohidrosis and hypohidrosis related symptoms, 12 (26.1 percent) had facial flushing, four (8.7 percent) had heat intolerance, one (2.2 percent) had lethargy, but no one had anhidrosis. Among the 17 patients, the mild group numbered 12 and the severe group totalled five. Hypohidrosis by $Neurocheck^{TM}$ was diagnosed in 16 patients. The overall measures of agreement between $Neurocheck^{TM}$ and the survey was 76.5 percent. The specificity of this test was 89.7 percent. Patients who showed a time delay after medication, especially over 3 minutes, were seen only in the severe group. Conclusion : $Neurocheck^{TM}$ could be clinically useful to detect and predict topiramate induced hypohidrosis in pediatric epileptic patients. We recommend that patients who show a delay over 3 minutes in $Neurocheck^{TM}$ test after topiramate initiation should be monitored for hypohydrosis.

목 적 : TPM를 복용중인 간질 환아들에서 소한증 관련 증상 발생률을 확인함과 더불어, 뉴로체크($Neurocheck^{TM}$) 발한 검사를 시행하여 비침습적으로 발한 감소 관련 증상을 비교 확인하고자 하였다. 방 법 : 2004년 10월부터 2005년 7월까지 전북대학병원 소아과에 내원한 환자 중 간질로 진단받고 TPM를 투여 시작한 환자 55명중 자료가 불충분한 9명을 제외하고 46명을 대상으로 하였다. 대상 환자는 약물 투여 전과 목표 용량에 도달 한 직후 가능한 빠른 시간에 뉴로체크를 이용한 발한 기능 검사를 시행하였고, 2005년 여름 소한증과 관련된 증상 발현 유무를 면담을 통해 확인하였다. 결 과 : 저자들은 전북대학교병원 소아과에서 부분발작으로 진단 받고 TPM를 복용중인 46명의 환아들을 대상으로 비침습적인 검사인 뉴로체크를 이용하여 TPM 유발성 발한 감소 증상을 예측하고자 하였으며 더불어 TPM으로 인한 발한 감소 증상의 유병률을 알아보고자 하였으며 다음과 같은 결과를 얻었다. 1) 설문조사상 여름 기간 동안 TPM 사용 중 소한증 관련 증상 발생률은 37.0% 였으며 완전 무한증은 없었고 경증의 비율은 26.1%, 중증의 비율은 10.9% 였다. 2) 뉴로체크 발한 검사상 발한 지연은 34.8% 였으며 변화 없는 경우는 54.3%, 발한이 증가한 경우는 10.9% 였다. 3) 설문조사 결과 발한 감소 관련 증상을 보인 환아들에서 뉴로체크 검사상 발한 감소를 보이는 경우는 46명 중 13명으로 76.5% 였으며 이중 설문조사 상 경증인 경우는 75.0%, 중증인 경우는 80%의 양성률을 보였다. 4) 뉴로체크 발한 검사상 TPM 사용전보다 3분 이상 지연된 경우 3분 이하에서보다 상대적으로 중증의 비율이 높았다. 결 론 : 소아연령에서 비침습적인 뉴로체크 발한 검사 방법으로 손쉽게 발한감소를 측정할 수 있었다. 뉴로체크 검사를 이용하여 TPM 유발성 발한 감소 관련 증상을 예측 할 수 있었으며, 특히 TPM 사용 전보다 3분 이상 지연된 경우 소한증 증상 발현이 현저하여 열감 불내성, 기면 혹은 열사병에 대한 주의가 필요할 것으로 생각된다.

Keywords

References

  1. Shechter T, Shorer Z, Kramer U, Lerman-Sagie T, Ronen E, Rotem R, et al. Adverse reactions of topiramate and lamotrigine in children. Pharmacoepidemiol Drug Saf 2005;14:187-92 https://doi.org/10.1002/pds.1041
  2. Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol 2000;15:S22-6 https://doi.org/10.1177/088307380001500105
  3. Yilmaz K, Tatli B, Yaramis A, Aydinli N, Caliskan M, Ozmen M. Symptomatic and asymptomatic hypohidrosis in children under topiramate treatment. Turk J Pediatr 2005;47:359-63
  4. Nieto-Barrera M, Nieto-Jimenez M, Candau R, Ruiz del Portal L. Anhidrosis and hyperthermia associated with treatment with topiramate. Rev Neurol 2002;34:114-6
  5. Ben-Zeev B, Watemberg N, Augarten A, Brand N, Yahav Y, Efrati O. Oligohidrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J Child Neurol 2003;18:254-7 https://doi.org/10.1177/08830738030180041001
  6. Cho NJ, Lee YJ, Lew Y, Kim DK, Lee SH. Evaluation of treatment effect of primary hyperhidrosis using skin surface hydrometer. Korean J Dermatol 1994;32:369-75
  7. Franz H, Philp HP, Harion BS. Studies on sweating. A new quantitative method of assaying sweat-delivery to circumscribed areas of the skin surface. J Invest Dermatol 1951;17:241-9 https://doi.org/10.1038/jid.1951.35
  8. SarKany I, Gaylarde P. A new method for demonstration of sweat gland activity. Br J Dermatol 1968;80:601-5 https://doi.org/10.1111/j.1365-2133.1968.tb12359.x
  9. David RH. Evaluation sweat gland activity with imprint techniques. J Invest Dermatol 1972;58:78-84 https://doi.org/10.1111/1523-1747.ep12551676
  10. Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders, I: normal sweat gland function. J Am Acad Dermatol 1989;20:537-63 https://doi.org/10.1016/S0190-9622(89)70063-3
  11. Ferrer T, Ramos MJ, Perez-Sales P, Perez-Jimenez A, Alvarez E. Sympathetic sudomotor function and aging. Muscle Nerve 1995;18:395-401 https://doi.org/10.1002/mus.880180405
  12. Ritter F, Glauser TA, Elterman RD, Wyllie E. Effectiveness, tolerability and safety of topiramate in children with partial-onset seizures. Epilepsia 2000;41:82-5 https://doi.org/10.1111/j.1528-1157.2000.tb02178.x
  13. Wilner A, Raymong K, Pollard R. Topiramate and metabolic acidosis. Epilepsia 1999;40:792-5 https://doi.org/10.1111/j.1528-1157.1999.tb00781.x
  14. Philippi H, Bor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002;43:744-7 https://doi.org/10.1046/j.1528-1157.2002.37201.x
  15. Takeoka M, Holmes GL, Thiele E, Bourgeois BF, Helmers SL, Duffy FH. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 2001;42:387-92 https://doi.org/10.1046/j.1528-1157.2001.04500.x
  16. Bjoro K, Gjerstad L, Bentdal O, Osnes S, Schrumpf E. Topiramate and fulminant liver failure. Lancet 1998;352:119-122
  17. Laskey AL, Korn DE, Moorjani BI, Patel NC, Tobias JD. Central hyperventilation related to administration of topiramate. Pediatr Neurol 2000;22:305-8 https://doi.org/10.1016/S0887-8994(99)00143-5
  18. Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Opthalmol 2001;119:1210-1
  19. Okamura A, Hayakawa F, Kuno K, Watanabe K. Oligohid-rosis caused by zonisamide. No To Hattatsu(Tokyo) 1996;28:44-7
  20. Carolis P, Magnifico F, Pierangeli G, Rinaldi R, Galeotti M, Cevoli S, et al. Transient hypohidrosis induced by topiramate. Epilepsia 2003;44:974-6 https://doi.org/10.1046/j.1528-1157.2003.40702.x
  21. Dogson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41:35-9 https://doi.org/10.1111/j.1528-1157.2000.tb02169.x
  22. Shank RP. Gardocki JF, Streeter AJ. An overview of the pre-clinical aspects of topiramate: pharmacology, pharmacokinetics and mechanisms of action. Epilepsia 2000;41:3-9 https://doi.org/10.1111/j.1528-1157.2000.tb02163.x
  23. Arcas J, Ferre T, Roche MC, Martinez A, Lopez V. Hypohidrosis related to the administration of topiramate to children. Epilepsia 2001;42:1363-5 https://doi.org/10.1046/j.1528-1157.2001.09201.x
  24. Shimizu T, Yamashita Y, Satoi M, Togo A, Wada N, Matsuishi T, et al. Heat stroke-like episode in child caused by zonisamide. Brain Dev 1997;19:366-9 https://doi.org/10.1016/S0387-7604(97)00029-6
  25. Tagami H, Kanamaru Y, Inoue K. Watersorption-desorption test of the skin in vivo for functional assessment of the stratum corneum. J Invest Dermatol 1982;78:425-8 https://doi.org/10.1111/1523-1747.ep12507756
  26. Sohn TS, Son HS, Yu JM, Cha BS, Min KW, Baik SH. Evaluation of the indicator test$(Neurocheck^{TM})$in the diagnosis of peripheral neuropathy among type 2 diabetic patients. J Kor Diabetes Assoc 2005;29:247-53
  27. Mathias CJ, Bannister R. Investigation of autonomic disorders. In: Bannister R, Mathias CJ, eds. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. 3rd ed. Oxford: Oxford University Press 1992:225-90
  28. Brigmann JV, Tashian RE, Spicer SS. Immunohistochemical localization of carbonic anhydrase II and I in ecrine sweat glands from control subjects and patients with cystic fibrosis. Am J Pathol 1983;112:250-5
  29. Chadwick DW, Marson T, Kadir Z. Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Epilepsia 1996;37:17-22 https://doi.org/10.1111/j.1528-1157.1996.tb06035.x
  30. Randall WC, Kimura KK. The pharmacology of sweating. Pharmacol Rev 1955;7:365-97
  31. Mikaeloff Y, Saint-Martin A, Mancini J. Topiramate:efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003;53:225-32 https://doi.org/10.1016/S0920-1211(03)00028-7